Vantage Partners

OCTOBER 27, 2020

Overview The 2020 ASAP BioPharma conference came to a close a month ago and marked another year of bringing together talented and thoughtful strategic alliance professionals to share and reflect on their experiences in this field.

Biopharma 83

Biopharma Life science Strategic alliances Alliance partnership 83

Jake Jorgovan

NOVEMBER 29, 2023

The Value of a Biopharma Consulting Firm Beyond mere compliance, these consultants offer strategic vision. BioPharma Consultants : Specializes in marketing, strategy, and corporate development services for the biotech and pharmaceutical industries, offering solutions from product launch plans to commercial support for fundraising.

Biopharmaceuticals 130

Biopharmaceuticals Biopharma Biotech Life science 130

Vantage Partners

NOVEMBER 17, 2020

Vantage Partners was proud to be the premier sponsor for Cambridge HealthTech Institute’s (CHI) 2020 Strategic Alliance Management Congress. As in the past, this conference featured insightful presentations from leaders across Biopharma alliance management.

Alliance management 83

Alliance management Strategic alliances Biopharma Alliance partnership 83

Frost & Sullivan

APRIL 21, 2021

TMO recorded the highest top-line Y-o-Y revenue growth of over 26% in 2020 in comparison to the last five years. 2 – The consolidation of PPD with TMO’s Patheon manufacturing unit creates a compelling end-to-end offering for biopharma sponsors and an opportunity to cross-sell services through revenue stream synergies.

Biopharma 98

Biopharma Biotech Banking 98

Frost & Sullivan

AUGUST 9, 2021

billion in 2020, expanding exponentially at a compound annual growth rate (CAGR) of 29.8%. Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. billion by 2025 from $1.23

Life science 98

Life science Biopharma Government Biopharmaceuticals 98

Frost & Sullivan

AUGUST 9, 2021

billion in 2020, expanding exponentially at a compound annual growth rate (CAGR) of 29.8%. Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data. billion by 2025 from $1.23

Life science 90

Life science Biopharma Government Biopharmaceuticals 90

Frost & Sullivan

JANUARY 28, 2021

trillion, up from $2 trillion in 2020. Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies.

Biopharma 98

Biopharma Government Ecosystems 98